Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Selected Balance Sheet Data (Details Textual)

v3.6.0.2
Note 2 - Selected Balance Sheet Data (Details Textual)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Jun. 30, 2016
USD ($)
Available-for-sale Securities $ 56,600 $ 56,600   $ 31,600
Payments to Acquire Available-for-sale Securities   1,625  
Inventory, Net 66,089 66,089   57,102
Inventory Valuation Reserves 24,000 24,000    
Other Assets, Noncurrent 42,694 42,694   1,922
Payments to Acquire Investments   $ 40,000  
Number of Reporting Units   3    
Astute Medical, Inc. [Member]        
Payments to Acquire Investments 40,000      
ChemoCentryx, Inc (CCXI) [Member]        
Available-for-sale Equity Securities, Gross Unrealized Gain   $ 17,700    
Available-for-sale Equity Securities, Amortized Cost Basis 29,500 29,500   29,500
Certificates of Deposit [Member] | CHINA        
Payments to Acquire Available-for-sale Securities   1,300    
Advanced Cell Diagnostics (ACD) [Member]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory       $ 9,600
Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities $ 5,100 $ 5,100